oxaliplatin,nab-paclitaxel,gemcitabine,5-fluorouracil,leucovorin
ipsen
['napoli-3', 'ipsen']
at the 2023, presented the positive results from phase iii napoli-3 trial. in patients with mpdac, first-line nalirifox displayed clinically relevant &amp; statistically significant improvement in os &amp; pfs compared to gem+nabp. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry